VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma

por Nadiminti, Kalyan, Singh Abbi, Kamal Kant, Mott, Sarah L, Dozeman, Lindsay, Tricot, Annick, Schultz, Allyson, Behrends, Sonya, Zhan, Fenghuang, Tricot, Guido
Publicado 2017